BioMedPartners
BioMedPartners is one of the leading European venture capital firms.
Business Model:
Revenue: $12.6M
Employees: 2-10
Rankings
Industries / Tags:
Detailed BioMedPartners Information
Geographic Data
Address: Elisabethenstr. 23
City: Basel
State: basel-country
Zip: 4051
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$75M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2013 | Middle Peak Medical | Series A | 0 |
| 1/2018 | Miracor Medical | Series D | 0 |
| 10/2016 | Miracor Medical | Series C | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 1/2015 | Miracor Medical | Series B | 5.3M |
| 12/2014 | Anergis | Series B | 14.9M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 8/2005 | Dolthera GmbH | Series B | 18M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 11/2014 | Curetis | Series B | 0 |
| 9/2005 | Bioheart | Venture Round | 0 |
| 4/2014 | Sequana Medical | Series C | 26.1M |
| 4/2007 | Affimed | Series B | 32M |
| 3/2014 | Inotrem | Series A | 25.1M |
| 10/2012 | Affimed | Series D | 20.1M |
| 12/2009 | Curetis | Series A | 27.9M |
| 9/2005 | Spinal Cord Therapeutics GmbH | Series A | 15.5M |
| 8/2009 | Spinelab | Series B | 10.2M |
| 9/2022 | Tricares | Series C | 0 |
| 2/2014 | Anergis | Series A | 8.9M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 3/2011 | Sequana Medical | Series B | 25.5M |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 4/2007 | Spinelab | Series A | 3.3M |
| 8/2006 | ESBATech | Series B | 41M |
| 10/2007 | idiag | Venture Round | 3.8M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 8/2008 | ESBATech | Series B | 22M |
| 5/2022 | Tubulis | Series B | 0 |
| 7/2008 | SuppreMol | Series B | 25M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 12.3M |
| 12/2020 | Noema Pharma | Series A | 60M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 4/2019 | Alentis Therapeutics | Series A | 12.3M |
| 4/2012 | Aleva Neurotherapeutics | Series B | 4.4M |
| 11/2009 | Activaero | Series A | 15.8M |
| 3/2004 | CareX SA | Series B | 32M |
| 3/2022 | Precirix | Series B | 0 |
| 11/2013 | Delenex Therapeutics | Series A | 8M |
| 10/2014 | ImevaX | Series A | 0 |
| 1/2011 | VAXIMM | Venture Round | 8M |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 9/2017 | Amal Therapeutics | Series B | 9.5M |
| 11/2018 | Amal Therapeutics | Series B | 32.6M |
| 9/2008 | Lumavita | Series A | 16.2M |
| 5/2012 | Spinelab | Series C | 4.8M |
| 11/2010 | Delenex Therapeutics | Series A | 14M |
| 2/2011 | Activaero | Series A | 0 |
| 11/2004 | Symetis | Series A | 9.6M |
| 9/2014 | Affimed | Series E | 0 |
| 12/2010 | SuppreMol | Series C | 20.4M |
| 6/2021 | Alentis Therapeutics | Series B | 66.8M |
| 6/2020 | TOLREMO therapeutics | Series A | 5M |
| 5/2016 | Aleva Neurotherapeutics | Series C | 18M |
| 8/2011 | Aleva Neurotherapeutics | Series A | 13.7M |
| 6/2018 | Tricares | Series B | 25.7M |
| 5/2011 | Delenex Therapeutics | Series A | 19.3M |
| 4/2016 | Anergis | Series C | 5.2M |
| 3/2011 | Anergis | Series A | 20M |
| 4/2010 | Affimed | Series C | 0 |
| 12/2019 | ImmunOs Therapeutics | Series A | 0 |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 11/2003 | Thommen Medical | Series C | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 5/2013 | SuppreMol | Series D | 12.3M |
| 10/2009 | Evolva | Series B | 27.8M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 12/2014 | AYOXXA | Series B | 2.9M |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 9/2018 | TOLREMO therapeutics | Series A | 9.3M |
| 11/2018 | Precirix | Series A | 41.9M |
| 10/2006 | Santhera Pharmaceuticals | Series C | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 12/2019 | Aleva Neurotherapeutics | Series E | 8.1M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 11/2014 | Humedics | Series C | 7.8M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 5/2022 | Tubulis | Series B | 0 |
| 3/2022 | Precirix | Series B | 0 |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 6/2021 | Alentis Therapeutics | Series B | 0 |
| 12/2020 | Noema Pharma | Series A | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
